This intricate connection suggests that targeting the IFI16-STING-IRF3 pathway and its associated PANoptosis mechanisms could offer novel therapeutic strategies for managing cardiometabolic diseases that have an inflammatory component, such as atherosclerosis. The gene discussed is IFI16; the disease is atherosclerosis.